MARCO and systemic sclerosis: To study the role of MARCO+ myeloid cells in the pathogenesis of multiorgan fibrosis in SSc, we developed an innovative therapeutic strategy targeting inflammatory monocytes and activated macrophages by leveraging the drug-like biological properties of carboxylated poly(lactic-co-glycolic) acid (PLG) nanoparticles.